SOPHION BIOSCIENCE A/S
Core data
Name | SOPHION BIOSCIENCE A/S |
Address | Industriparken 39, 2750, Ballerup |
Founded | Feb 7, 2000 |
| 90 / 83 | |
Locations (P-units) | 1View locations |
Website | https://sophion.com/ |
 LinkedIn | sophion-bioscience-as |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Name | SOPHION BIOSCIENCE A/S |
Address | Industriparken 39, 2750, Ballerup |
Founded | Feb 7, 2000 |
| 90 / 83 |
Locations (P-units) | 1View locations |
Website | https://sophion.com/ |
| LinkedIn | sophion-bioscience-as |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Keep track of SOPHION BIOSCIENCE A/S
Description
Sophion Bioscience is a global life science company specializing in automated patch clamp and cell line solutions, with technical, biological, and application support for ion channel research and drug discovery.
Sophion Bioscience develops and manufactures automated patch clamp and cell line solutions, including QPatch and Qube 384 platforms, to support ion channel research, drug discovery, and electrophysiology experiments.
Company's own description on virk.dk
Core activities Sophion Bioscience is a leading global life science company founded in 2000 by a group of passionate electro-physiologists, with the aim of making patch clamping objective and independent of user skills. With the launch of our organ-on-a-chip technology in 2025, Sophion Bioscience now specializes in automated and high throughput solutions for life sciences. Sophion Bioscience works closely with academic institutions, contract research organizations, and leading biotech and pharmaceutical companies to create effective assays for screening and characterization. Our solutions empower the study of drug targets and candidates at the bench, reducing development time in discovery and reducing risk in clinical trials. Sophion Bioscience’s primary activities are development, production, sale, support and service of automated and high throughput solutions for life sciences.
Products & services
Automated patch clamp solutions · Cell line solutions · QPatch · QPatch Compact · Qube 384 · Technical support · Biological support · Application support · Instrument selector
Industries
Life science · Drug discovery · Ion channel research · Electrophysiology
Customer types
Researchers · Drug discovery partners · Life science customers
Analysis by AI ✨
Sophion Bioscience recorded a substantially lower result in 2025: its annual report shows a profit after tax of DKK 4.4 million, compared with DKK 39.1 million in 2024. Gross profit fell from DKK 119.6 million to DKK 102.1 million. Employees increased from 64 in August 2024 to 90 in August 2026, while FTEs rose from 63 to 83.
The annual report describes the launch of a new version of Qube 384 and the organ-on-a-chip technology Ethica M; the first Ethica M sales took place in the fourth quarter of 2025. It also notes investments in the organization, production, quality assurance, and research and development, as well as financing facilities established with the owners and refinanced with external facilities in January 2026.
Sophion Bioscience is currently 100% owned by Sapphire Bioscience Holding ApS. Sweden’s Sophion Holding AB owned Sophion Bioscience 100% from 1 February 2012 to 27 June 2017. Sapphire Bioscience Holding ApS is currently owned by TTJ Invest Holding ApS, with a registered ownership interest of 25–33.32%, and Norway’s Vind Industry AS, with 66.67–89.99%.
AI-generated texts are based on registered information, which may be delayed or incomplete. Errors may occur.
Financials
| Reporting period | 2025DKK | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | 102,112,000 | ||||||||||
| Operating profit | 7,640,000 | ||||||||||
| Profit before tax | 5,218,000 | ||||||||||
| Net income | 4,354,000 | ||||||||||
| Total assets | 237,559,000 | ||||||||||
| Equity | 178,418,000 | ||||||||||
| Avg. employees | 97 | ||||||||||
2015–2025 Unlock financial history | |||||||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Contact
From sophion.com
| Contact | Phone | |
|---|---|---|
| Main | — | in**@sophion.comShow full |
Gazelle
2011Børsen GazelleBørsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
People
| Person | Roles | Titles |
|---|---|---|
| Peter Max | Roles Board | TitlesBESTYRELSESMEDLEM |
| Thais Taaning Johansen | Roles Board | TitlesBESTYRELSESMEDLEM |
| Michel Krall Jürgens | Roles Management | TitlesADM. DIR. |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| Dansk Revision Slagelse Godkendt revisionsaktieselskab | AuditorKim Thomas Nielsen | RoleState authorized public accountant | FromMay 20, 2026 |
| Dansk Revision Slagelse Godkendt revisionsaktieselskab, | AuditorKim Thomas Nielsen | RoleState authorized public accountant | FromMay 20, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
| Ownership100 % | Voting rights100 % | FromJun 27, 2017 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| 🇳🇴Vind Industry AS | Ownership through | 66.67–89.99 % |
| Thais Taaning Johansen | Ownership through | 25–33.32 % |